Scientists report diabetes drug helps with weight loss for various body types
- Replies 7
The quest for effective weight loss solutions has been a long and challenging journey for many, but a recent study has shed light on a promising new avenue.
The diabetes medication tirzepatide, which has been making waves in the medical community, has now been found to aid in weight loss across a spectrum of body types, regardless of a patient's body mass index (BMI).
This groundbreaking research is set to be presented at the prestigious European Congress on Obesity in Venice, and it's catching the attention of healthcare professionals and patients alike.
The study, spearheaded by Professor Carel Le Roux from University College Dublin and Dr Louis J. Aronne, Director of the Comprehensive Weight Control Centre, has revealed that tirzepatide, already known for its role in managing type 2 diabetes, could be a game-changer in the realm of weight management.
The drug, which goes by the brand name Zepbound in the United States, received approval from the US Food and Drug Administration for chronic weight management in adults categorised as 'obese' or 'overweight.'
In a series of randomised controlled trials, researchers observed the effects of tirzepatide on patients with varying BMIs, all of whom had at least one weight-related comorbidity.
The participants, some with type 2 diabetes and some without, were given the injectable drug alongside a placebo.
For 72 to 88 weeks, and in conjunction with diet and exercise, those treated with tirzepatide experienced significant weight loss.
One of the most intriguing findings of the study was that the duration of a participant's obesity or overweight status did not influence the drug's effectiveness in aiding weight loss.
'Regardless of baseline BMI, tirzepatide consistently reduced body weight versus placebo in people with obesity across the SURMOUNT 1-4 trials,' Dr Aronne stated, highlighting the drug's broad potential.
‘Further analyses are needed to explore and understand why patients with type 2 diabetes have less weight loss in these trials than those without type 2 diabetes.’
While the study is still awaiting peer review, the initial results are promising.
Professor Le Roux expressed optimism about the drug's potential, stating, 'Tirzepatide is one of the most effective treatments we have for the disease of obesity, and not only can we control the disease but we are also able to disrupt the complications of obesity such as type 2 diabetes.'
It comes after when the Australian Diabetes Society shared that new medications could help treat diabetes as well as weight loss.
However, the group is advocating for these drugs to be more accessible to the public. You can read more about the story here.
As with any medication, it's crucial to consult with a healthcare provider to discuss the potential benefits and risks and to determine whether tirzepatide or any other medication is an appropriate part of your weight management plan.
What do you think about this story? Have you or a loved one had experience with this medication? Share your thoughts and experiences in the comments below.
The diabetes medication tirzepatide, which has been making waves in the medical community, has now been found to aid in weight loss across a spectrum of body types, regardless of a patient's body mass index (BMI).
This groundbreaking research is set to be presented at the prestigious European Congress on Obesity in Venice, and it's catching the attention of healthcare professionals and patients alike.
The study, spearheaded by Professor Carel Le Roux from University College Dublin and Dr Louis J. Aronne, Director of the Comprehensive Weight Control Centre, has revealed that tirzepatide, already known for its role in managing type 2 diabetes, could be a game-changer in the realm of weight management.
Scientists reported that tirzepatide might help with weight loss regardless of body type. Credit: Zepbound
The drug, which goes by the brand name Zepbound in the United States, received approval from the US Food and Drug Administration for chronic weight management in adults categorised as 'obese' or 'overweight.'
In a series of randomised controlled trials, researchers observed the effects of tirzepatide on patients with varying BMIs, all of whom had at least one weight-related comorbidity.
The participants, some with type 2 diabetes and some without, were given the injectable drug alongside a placebo.
For 72 to 88 weeks, and in conjunction with diet and exercise, those treated with tirzepatide experienced significant weight loss.
One of the most intriguing findings of the study was that the duration of a participant's obesity or overweight status did not influence the drug's effectiveness in aiding weight loss.
'Regardless of baseline BMI, tirzepatide consistently reduced body weight versus placebo in people with obesity across the SURMOUNT 1-4 trials,' Dr Aronne stated, highlighting the drug's broad potential.
‘Further analyses are needed to explore and understand why patients with type 2 diabetes have less weight loss in these trials than those without type 2 diabetes.’
While the study is still awaiting peer review, the initial results are promising.
Professor Le Roux expressed optimism about the drug's potential, stating, 'Tirzepatide is one of the most effective treatments we have for the disease of obesity, and not only can we control the disease but we are also able to disrupt the complications of obesity such as type 2 diabetes.'
It comes after when the Australian Diabetes Society shared that new medications could help treat diabetes as well as weight loss.
However, the group is advocating for these drugs to be more accessible to the public. You can read more about the story here.
As with any medication, it's crucial to consult with a healthcare provider to discuss the potential benefits and risks and to determine whether tirzepatide or any other medication is an appropriate part of your weight management plan.
.png){kind=icon}
